SCHEDULE 13G/A: T. Rowe Price Amends Ionis Pharma Stake to 8.3%

T. Rowe Price Investment Management, Inc. has filed an Amendment No. 3 to its Schedule 13G, disclosing an 8.3% beneficial ownership stake in Ionis Pharmaceuticals Inc. common stock as of September 30, 2025.

Summary

• T. Rowe Price Investment Management, Inc. reported beneficial ownership of 13,157,114 shares of Ionis Pharmaceuticals Inc. common stock.
• This represents an 8.3% stake in the company's common stock.
• The reporting person holds sole voting power over 13,044,284 shares and sole dispositive power over 13,157,114 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The filing is an Amendment No. 3 to a previously filed Schedule 13G.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership by an institutional investor. It does not contain information that inherently suggests a positive or negative sentiment about the company's performance, but rather reflects an investment decision.

Positives

• A significant stake by a major institutional investor like T. Rowe Price can signal confidence in Ionis Pharmaceuticals' long-term prospects.
• The investment is held in the ordinary course of business, indicating a passive investment strategy rather than an activist one.

Future Outlook

NA

Industry Context

Ionis Pharmaceuticals operates in the biotechnology and pharmaceutical sector, focusing on RNA-targeted therapeutics. T. Rowe Price Investment Management, Inc. is a prominent global asset manager, and its significant stake indicates institutional interest in the biotech industry, potentially driven by the company's drug pipeline or market position.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by T. Rowe Price may be viewed positively, potentially signaling confidence in the company's value.
• Management: Awareness of a large institutional holder can influence management's strategic decisions and communication.

Key Dates

Keywords

Ionis Pharmaceuticals, T. Rowe Price, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Biotechnology, Pharmaceuticals